R. Chen, X. Zhou, J. Liu, and G. Huang, Relationship between the expression of PD-1/PD-L1 and 18 F-FDG uptake in bladder cancer, Eur J Nucl Med Mol Imaging, 2019.

M. Eckstein, P. Erben, M. C. Kriegmair, T. S. Worst, C. A. Weiß et al., Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab, Eur J Cancer, vol.2019, pp.234-243

J. Bellmunt, T. Powles, and N. J. Vogelzang, A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now, Cancer Treat Rev, vol.54, pp.58-67, 2017.

M. Rouanne, M. Roumiguié, N. Houédé, A. Masson-lecomte, C. P. Pignot et al., Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways, World J Urol, vol.36, issue.11, pp.1727-1740, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02292092

A. Girard, M. Rouanne, S. Taconet, C. Radulescu, Y. Neuzillet et al., Integrated analysis of 18 F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer, Eur Radiol, 2019.

H. Öztürk, Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose PositronEmission Tomography/Computed Tomography, Cancer Res Treat, vol.47, issue.4, pp.834-877, 2015.

E. F. Burgess, C. Livasy, A. Hartman, M. M. Robinson, J. Symanowski et al., Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions, Urol Oncol, 2019.

M. Soret, S. L. Bacharach, and I. Buvat, Partial-volume effect in PET tumor imaging, J Nucl Med, vol.48, issue.6, pp.932-977, 2007.

M. Rouanne, R. Betari, C. Radulescu, A. Goubar, N. Signolle et al., Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer, Eur J Cancer, vol.108, pp.111-119, 2019.